Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis.

In 30 seconds

This randomized controlled trial analyzed the effects of evolocumab on plaque stabilization in patients with acute coronary syndrome and varying lipoprotein(a) levels. In patients with high Lp(a) levels, evolocumab significantly reduced LDL cholesterol (21.7 ± 10.3 vs 94.5 ± 22.9 mg/dL; P < 0.001) and increased minimum fibrous cap thickness (+51.6 ± 40.9 vs +12.4 ± 23.9 μm; P < 0.001) compared to placebo.

Key findings

• Evolocumab reduced LDL cholesterol in high Lp(a) patients to 21.7 ± 10.3 mg/dL vs 94.5 ± 22.9 mg/dL for placebo (P < 0.001).
• In high Lp(a) patients, minimum fibrous cap thickness increased by +51.6 ± 40.9 μm with evolocumab vs +12.4 ± 23.9 μm with placebo (P < 0.001).
• Evolocumab also lowered Lp(a) levels in high Lp(a) patients to 156.0 (136.0, 187.0) nmol/L vs 204.0 (170.5, 290.5) nmol/L for placebo (P = 0.007).
• No significant differences in plaque stabilization were observed in low Lp(a) patients between evolocumab and placebo.

Why it matters

Understanding the differential effects of evolocumab based on Lp(a) levels can guide clinicians in identifying patients who may benefit most from intensive lipid-lowering therapy, potentially improving outcomes in those with acute coronary syndrome.